Why shares of Aegerion soared more than 30% today.
Aegerion Pharmaceuticals (NASDAQ: AEGR) is up 30%, thanks to a presentation at the Bank of America Merrill Lynch 2013 Healthcare Conference. Analysts have literally rushed out and threw upgrades at the stock after the company announced a price hike for HoFH drug Juxtapid.
In this video, health-care analyst David Williamson discusses what these events mean for investors in Aegerion, and also for its competitors.
David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.
The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
